A recent study discovered that HSF1 enhances prostate cancer cell resistance to ferroptosis by modulating HSPE1, and that HSF1 knockdown can promote prostate cancer cell sensitivity to RSL3 therapy (91). This evidence concerns the gene HSPE1 and prostate carcinoma.